Madrigal Pharmaceuticals ... (MDGL)
Madrigal Pharmaceuticals Statistics
Share Statistics
Madrigal Pharmaceuticals has 22.08M shares outstanding. The number of shares has increased by 3.61% in one year.
| Shares Outstanding | 22.08M |
| Shares Change (YoY) | 3.61% |
| Shares Change (QoQ) | 1.24% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 19.95M |
| Failed to Deliver (FTD) Shares | 13.59K |
| FTD / Avg. Volume | 3.3% |
Short Selling Information
The latest short interest is 4.08M, so 18.72% of the outstanding shares have been sold short.
| Short Interest | 4.08M |
| Short % of Shares Out | 18.72% |
| Short % of Float | 22.21% |
| Short Ratio (days to cover) | 10.54 |
Valuation Ratios
The PE ratio is -14.09 and the forward PE ratio is -24.13. Madrigal Pharmaceuticals's PEG ratio is -1.47.
| PE Ratio | -14.09 |
| Forward PE | -24.13 |
| PS Ratio | 36.44 |
| Forward PS | 1.7 |
| PB Ratio | 8.7 |
| P/FCF Ratio | -14.36 |
| PEG Ratio | -1.47 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Madrigal Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.1, with a Debt / Equity ratio of 0.
| Current Ratio | 6.1 |
| Quick Ratio | 5.9 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -33.94 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $341.16K |
| Profits Per Employee | $-882.37K |
| Employee Count | 528 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.18 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 25.41% in the last 52 weeks. The beta is -0.69, so Madrigal Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.69 |
| 52-Week Price Change | 25.41% |
| 50-Day Moving Average | 332.34 |
| 200-Day Moving Average | 288.73 |
| Relative Strength Index (RSI) | 41.42 |
| Average Volume (20 Days) | 412.1K |
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M and earned -465.89M in profits. Earnings per share was -21.9.
| Revenue | 180.13M |
| Gross Profit | 173.9M |
| Operating Income | -497.88M |
| Net Income | -465.89M |
| EBITDA | -450.13M |
| EBIT | -451.22M |
| Earnings Per Share (EPS) | -21.9 |
Balance Sheet
The company has 100.02M in cash and 983K in debt, giving a net cash position of 99.04M.
| Cash & Cash Equivalents | 100.02M |
| Total Debt | 983K |
| Net Cash | 99.04M |
| Retained Earnings | -1.8B |
| Total Assets | 1.04B |
| Working Capital | 863.65M |
Cash Flow
In the last 12 months, operating cash flow was -455.57M and capital expenditures -1.46M, giving a free cash flow of -457.03M.
| Operating Cash Flow | -455.57M |
| Capital Expenditures | -1.46M |
| Free Cash Flow | -457.03M |
| FCF Per Share | -21.48 |
Margins
Gross margin is 96.54%, with operating and profit margins of -276.39% and -258.64%.
| Gross Margin | 96.54% |
| Operating Margin | -276.39% |
| Pretax Margin | -258.64% |
| Profit Margin | -258.64% |
| EBITDA Margin | -249.88% |
| EBIT Margin | -276.39% |
| FCF Margin | -253.72% |
Dividends & Yields
MDGL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MDGL is $405, which is 31.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $405 |
| Price Target Difference | 31.7% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Jul 25, 2016. It was a backward split with a ratio of 1:35.
| Last Split Date | Jul 25, 2016 |
| Split Type | backward |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | 11.25 |
| Piotroski F-Score | 4 |